A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2
18+
23 sites in AZ, CA, FL +11
What this study is about
This Phase 2 study is focused on people with multiple myeloma. The primary outcome being measured is Overall Response Rate (ORR).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Overall Response Rate (ORR)
Secondary: Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score, Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Scale Score, Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score, Complete Response (CR) or Better Rate, Duration of Response (DoR), Number of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity, Overall Survival (OS), Percentage of Participants With Meaningful Improvement in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
Oncology